{"url_path":"/sec/adpt/8-k/2026-06-09/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1478320/0001193125-26-263844-index.html","accession_number":"0001193125-26-263844","cik":"0001478320","ticker":"ADPT","issuer_name":"Adaptive Biotechnologies Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1478320/0001193125-26-263844-index.html","primary_entity_key":"0001478320","primary_entity_name":"Adaptive Biotechnologies Corp"},"word_count":340,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 5, 2026, Adaptive Biotechnologies Corporation (the \"Company\") held its annual meeting of shareholders (the \"Annual Meeting\") pursuant to notice duly given. Three proposals were presented for voting: Proposal 1: election of two Class I directors to the Board of Directors (Robert Hershberg, PhD, MD and Katey Owen, PhD); Proposal 2: an advisory request concerning compensation for the Company's 2025 named executive officers; and, Proposal 3: ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. Each of the proposals was described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026. A quorum of the shareholders voted by the conclusion of the Annual Meeting. The final results of the voting are set forth below.\n\n \n\nProposal 1: Election of Two Class I Directors\n\n \n\nRobert Hershberg PhD, MD\n\nVotes Submitted\n\nAs % of Proposal Votes\n\nBroker Non Vote\n\nFor\n\n93,188,652\n\n71.81 %\n\n13,570,859\n\nAgainst\n\n-\n\n-\n\nWithhold/Abstain\n\n36,573,708\n\n28.19 %\n\nKatey Owen, PhD\n\nVotes Submitted\n\nAs % of Proposal Votes\n\nBroker Non Vote\n\nFor\n\n126,803,695\n\n97.72 %\n\n13,570,859\n\n \n\nAgainst\n\n-\n\n-\n\nWithhold/Abstain\n\n2,958,666\n\n2.28 %\n\n \n\nProposal 2: Advisory Vote Concerning the 2025 Compensation of the Company's Named Executive Officers\n\n \n\nVotes Submitted\n\nAs % of Proposal Votes\n\nBroker Non Vote\n\nFor\n\n125,287,618\n\n96.55 %\n\n13,570,859\n\nAgainst\n\n4,316,144\n\n3.33 %\n\nWithhold/Abstain\n\n158,599\n\n0.12 %\n\n \n\nProposal 3: Ramification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2026\n\n \n\nVotes Submitted\n\nAs % of Proposal Votes\n\nBroker Non Vote\n\nFor\n\n142,609,643\n\n99.50 %\n\n0\n\nAgainst\n\n484,798\n\n0.34 %\n\nWithhold/Abstain\n\n238,779\n\n0.17 %\n\n##  \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAdaptive Biotechnologies Corporation\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 9, 2026\n\nBy:\n\n/s/ Kyle Piskel\n\n \n\n \n\n \n\nKyle Piskel\nChief Financial Officer"}